Publicaciones científicas
The rise of TIM-3: A promising immune target in diffuse midline gliomas
Iker Ausejo-Mauleon 1 2 3 , Sara Nuin 1 2 3 , Marta M Alonso 1 2 3
Despite the poor prognostic of paediatric brain tumours, research specifically focused on these tumours has been historically scarce.
Consequently, paediatric patients have been treated with therapeutic regimens based on those of adults, which have failed. It is now known that the biogenesis of these tumours is different from adults’ tumours, not to mention the bio-physiological differences between paediatric and adult patients.
Despite the advances in the knowledge of their molecular characteristics, paediatric Central Nervous System (CNS) tumours continue to be the leading cause of cancer death in children aged 0−16 years.1
Diffuse midline gliomas, encompassing diffuse intrinsic pontine gliomas (DIPGs), are the most aggressive paediatric brain tumours. These tumours arise from midline structures, including the pons, thalamus, cerebellum and spinal cord, and are inoperable due to their location in vital and intricate brain structures.
Their meagre survival has not changed despite the combination of conventional treatments, including radiation, chemotherapy and targeted therapies, emphasizing the urgent need for effective treatments.2
CITA DEL ARTÍCULO Clin Transl Med. 2024 Jan;14(1):e1536. doi: 10.1002/ctm2.1536
Nuestros autores
